Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial
Authors' conclusion
In this RCT, treatment of PA on the basis of non-ACTH-stimulated or ACTH-stimulated AVS did not lead to significant differences in clinical outcomes for the patients. These results suggest that ACTH stimulation during AVS may not have clinical benefit, at least in the Chinese population.
Study context
- Population
- Patients with primary aldosteronism (PA) aged 18 to 70 years, tertiary hospital in China, July 2020 to February 2023
- Participants
- 228 patients
- Comparison
- ACTH-stimulated vs non-ACTH-stimulated adrenal venous sampling (AVS)
- ACTHn = 113
- Non-ACTHn = 115reference
- Primary endpoint
- Proportion of patients with complete biochemical remission
- Follow-up
- 12 months
Methodological detailssingle-centre, tertiary hospital
- Single-centre
- Tertiary hospital
Primary result
As reported in the abstract
Complete biochemical remission · 12 months
P = 0.79
Secondary outcomes
Complete clinical remission · 12 months · no significant difference
P = 0.40
Adrenalectomy
Antihypertensive intensity and successful bilateral adrenal vein catheterization
- Antihypertensive intensity and successful bilateral catheterization did not significantly differ between groups
Safety
- Incidence of adverse events did not significantly differ between non-ACTH and ACTH groups
Original publication
Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial. JAMA Netw Open. Published 2 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →